Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The hypothesis to be tested is that the bioavailability of the new 30-mg vial is similar to
that of the current approved 15 -mg vials. In addition, the SC injection using the new 30-mg
vial is safe and well-tolerated.